Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor
详细信息 查看全文
- 作者：Maria Loreto Bravo ; Mauricio P. Pinto ; Ibeth Gonzalez ; Barbara Oliva…
- 关键词：Progesterone ; Tissue factor ; mPRO ; Progesterone receptor ; Breast cancer
- 刊名：Endocrine
- 出版年：2015
- 出版时间：February 2015
- 年：2015
- 卷：48
- 期：1
- 页码：309-320
- 全文大小：1,223 KB
- 参考文献：1. B. Mulac-Jericevic, O.M. Conneely, Reproductive tissue selective actions of progesterone receptors. Reproduction. 128(2), 139-46 (2004). doi:10.1530/rep.1.00189 CrossRef
2. C. Campagnoli, C. Abba, S. Ambroggio, C. Peris, Pregnancy, progesterone and progestins in relation to breast cancer risk. J. steroid biochem. mol. biol. 97(5), 441-50 (2005). doi:10.1016/j.jsbmb.2005.08.015 CrossRef
3. A.R. Daniel, T.P. Knutson, C.A. Lange, Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol. Cell. Endocrinol. 308(1-), 47-2 (2009). doi:10.1016/j.mce.2009.01.004 CrossRef
4. K.B. Horwitz, P.L. Sheridan, L.L. Wei, N.L. Krett, Human progesterone receptors: synthesis, structure, and phosphorylation. Prog. Clin. Biol. Res. 322, 41-2 (1990)
5. V. Beral, Million Women Study, C.: breast cancer and hormone-replacement therapy in the million women study. Lancet. 362(9382), 419-27 (2003) CrossRef
6. A. Carvajal, N. Espinoza, S. Kato, M. Pinto, A. Sadarangani, C. Monso, E. Aranda, M. Villalon, J.K. Richer, K.B. Horwitz, J.J. Brosens, G.I. Owen, Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75. Breast Cancer Res. Treat. 94(2), 171-83 (2005). doi:10.1007/s10549-005-7726-6 CrossRef
7. D.S. Goodsell, The molecular perspective: tissue factor. Oncologist. 11(7), 849-50 (2006). doi:10.1634/theoncologist.11-7-849 CrossRef
8. S. Kato, M. Pinto, A. Carvajal, N. Espinoza, C. Monso, A. Sadarangani, M. Villalon, J.J. Brosens, J.O. White, J.K. Richer, K.B. Horwitz, G.I. Owen, Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J. clin. endocrinol. metab. 90(2), 1181-188 (2005). doi:10.1210/jc.2004-0857 CrossRef
9. J. Chen, A. Bierhaus, S. Schiekofer, M. Andrassy, B. Chen, D.M. Stern, P.P. Nawroth, Tissue factor–a receptor involved in the control of cellular properties, including angiogenesis. Thromb. Haemost. 86(1), 334-45 (2001)
10. A. Falanga, T. Barbui, F.R. Rickles, Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin. Thromb. Hemost. 34(2), 204-10 (2008). doi:10.1055/s-2008-1079262 CrossRef
11. R.A. Medina, E. Aranda, C. Verdugo, S. Kato, G.I. Owen, The action of ovarian hormones in cardiovascular disease. Biol. Res. 36(3-), 325-41 (2003)
12. G.J. Caine, P.S. Stonelake, G.Y. Lip, S.T. Kehoe, The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 4(6), 465-73 (2002). doi:10.1038/sj.neo.7900263 CrossRef
13. M.B. Donati, Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb. Haemost. 74(1), 278-81 (1995)
14. F.R. Rickles, R.L. Edwards, Activation of blood coagulation in cancer: trousseau’s syndrome revisited. Blood 62(1), 14-1 (1983)
15. C. Campagnoli, F. Clavel-Chapelon, R. Kaaks, C. Peris, F. Berrino, Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J. steroid biochem. mol. biol.- 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, general;
- 出版者：Springer US
- ISSN：1559-0100
文摘
To characterize the molecular mechanism and map the response element used by progesterone (P) to upregulate tissue factor (TF) in breast cancer cells. TF expression and mRNA levels were analyzed in breast cancer ZR-75 and T47D cells, using Western blot and real-time PCR, respectively. Mapping of the TF promoter was performed using luciferase vectors. Progesterone receptor (PR) and specificity protein 1 (Sp1) binding to the TF promoter were analyzed by chromatin immuno precipitation assay. Specific or selective inhibitors were used for the MEK1/2 and the c-Src pathways (UO126 and PP2, respectively). TF mRNA increase peaks at 18?h following P treatment in ZR-75 and T47D cells. P upregulation occurs via a transcriptional mechanism that depends on PR and MEK1/2 activation, PR and Sp1 transcription factors bind to a region in the TF promoter that contains three Sp1 sites. TF mRNA upregulation requires an intact PR proline-rich site (mPRO), but it is independent from c-Src. TF upregulation by P is mediated by Sp1 sites in the TF promoter region. Transcriptional upregulation in breast cancer cells occurs via a new mechanism that requires MEK1/2 activation and the mPRO site but independent of c-Src activity. PR Phosphorylation at serine 294 and 345 is not essential.